Press release
Epidermolysis Bullosa Pipeline Assessment, 2024: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | RegeneRx Biopharma, BridgeBio Pharma
The Epidermolysis Bullosa Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Epidermolysis Bullosa Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Epidermolysis Bullosa Market.
Some of the key takeaways from the Epidermolysis Bullosa Pipeline Report:
* Companies across the globe are diligently working toward developing novel Epidermolysis Bullosa treatment therapies with a considerable amount of success over the years. Epidermolysis Bullosa Key players such as - Berg Pharma, Holostem Terapie Avanzate, Aegle Therapeutics, RegeneRx Biopharmaceuticals, BridgeBio Pharma, InMed Pharmaceuticals, Fibrocell Science, Krystal Biotech, and others, are developing therapies for the Epidermolysis Bullosa treatment
* Epidermolysis Bullosa Emerging therapies such as - BPM31510, HOLOGENE-17,AGLE102, RGN-137, PTR-01, INM-755, Dabocemagene autoficel, VYJUVEK, and others are expected to have a significant impact on the Epidermolysis Bullosa market in the coming years.
* In December 2023, The FDA has authorized the use of birch triterpenes (Filsuvez, Chiesi Global Rare Diseases) topical gel for the treatment of partial thickness wounds associated with junctional and dystrophic epidermolysis bullosa (EB). Chiesi Global Rare Diseases also affirmed that this new medication stands as the sole FDA-approved option for patients diagnosed with junctional Epidermolysis Bullosa. The FDA's decision was grounded on findings from the phase 3 EASE trial (Identifier: NCT03068780), which involved 223 participants across 58 sites in 28 countries. The trial encompassed a three-month double-blind, randomized controlled phase followed by a 24-month open-label, single-arm phase.
Epidermolysis Bullosa Overview
Epidermolysis bullosa (EB) is a rare genetic disorder characterized by extremely fragile skin that is prone to blistering and tearing from minor friction or trauma. It is caused by mutations in genes responsible for producing proteins that help to anchor the layers of the skin together. As a result, individuals with EB experience painful blisters and sores on their skin, as well as in the mucous membranes lining the mouth, esophagus, and other organs.
Get a Free Sample PDF Report to know more about Epidermolysis Bullosa Pipeline Assessment-
https://www.delveinsight.com/report-store/epidermolysis-bullosa-pipeline-insight [https://www.delveinsight.com/report-store/epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Epidermolysis Bullosa Pipeline Therapeutics Assessment
* Epidermolysis Bullosa Assessment by Product Type
* Epidermolysis Bullosa By Stage and Product Type
* Epidermolysis Bullosa Assessment by Route of Administration
* Epidermolysis Bullosa By Stage and Route of Administration
* Epidermolysis Bullosa Assessment by Molecule Type
* Epidermolysis Bullosa by Stage and Molecule Type
DelveInsight's Epidermolysis Bullosa Report covers around 15+ products under different phases of clinical development like
* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration
Further Epidermolysis Bullosa product details are provided in the report. Download the Epidermolysis Bullosa pipeline report to learn more about the emerging Epidermolysis Bullosa therapies [https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Epidermolysis Bullosa Drugs Under Different Phases of Clinical Development Include:
* BPM31510: Berg Pharma
* HOLOGENE-17: Holostem Terapie Avanzate
* AGLE102: Aegle Therapeutics
* RGN-137: RegeneRx Biopharmaceuticals
* PTR-01: BridgeBio Pharma
* INM-755: InMed Pharmaceuticals
* Dabocemagene autoficel: Fibrocell Science
* VYJUVEK: Krystal Biotech
Epidermolysis Bullosa Pipeline Analysis:
The Epidermolysis Bullosa pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the Epidermolysis Bullosa treatment with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epidermolysis Bullosa Treatment.
* Epidermolysis Bullosa key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Epidermolysis Bullosa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epidermolysis Bullosa market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Epidermolysis Bullosa drugs and therapies [https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Epidermolysis Bullosa Pipeline Market Drivers
* Improving Healthcare Infrastructure
* Demand for New and Effective Drugs
Epidermolysis Bullosa Pipeline Market Barriers
* Currently no cure for all types of Epidermolysis Bullosa (DEB)
* Making a diagnosis for a genetic or rare disease is often challenging
Scope of Epidermolysis Bullosa Pipeline Drug Insight
* Coverage: Global
* Key Epidermolysis Bullosa Companies: Berg Pharma, Holostem Terapie Avanzate, Aegle Therapeutics, RegeneRx Biopharmaceuticals, BridgeBio Pharma, InMed Pharmaceuticals, Fibrocell Science, Krystal Biotech, and others
* Key Epidermolysis Bullosa Therapies: BPM31510, HOLOGENE-17,AGLE102, RGN-137, PTR-01, INM-755, Dabocemagene autoficel, VYJUVEK, and others
* Epidermolysis Bullosa Therapeutic Assessment: Epidermolysis Bullosa current marketed and Epidermolysis Bullosa emerging therapies
* Epidermolysis Bullosa Market Dynamics: Epidermolysis Bullosa market drivers and Epidermolysis Bullosa market barriers
Request for Sample PDF Report for Epidermolysis Bullosa Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/epidermolysis-bullosa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1
Epidermolysis Bullosa Report Introduction
2
Epidermolysis Bullosa Executive Summary
3
Epidermolysis Bullosa Overview
4
Epidermolysis Bullosa- Analytical Perspective In-depth Commercial Assessment
5
Epidermolysis Bullosa Pipeline Therapeutics
6
Epidermolysis Bullosa Late Stage Products (Phase II/III)
7
Epidermolysis Bullosa Mid Stage Products (Phase II)
8
Epidermolysis Bullosa Early Stage Products (Phase I)
9
Epidermolysis Bullosa Preclinical Stage Products
10
Epidermolysis Bullosa Therapeutics Assessment
11
Epidermolysis Bullosa Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Epidermolysis Bullosa Key Companies
14
Epidermolysis Bullosa Key Products
15
Epidermolysis Bullosa Unmet Needs
16
Epidermolysis Bullosa Market Drivers and Barriers
17
Epidermolysis Bullosa Future Perspectives and Conclusion
18
Epidermolysis Bullosa Analyst Views
19
Appendix
20
About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=epidermolysis-bullosa-pipeline-assessment-2024-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-and-growth-prospects-regenerx-biopharma-bridgebio-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Epidermolysis Bullosa Pipeline Assessment, 2024: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | RegeneRx Biopharma, BridgeBio Pharma here
News-ID: 3449511 • Views: …
More Releases from ABNewswire
MojiWeather Reveals Positive Reviews and Stellar User Experience for Weather For …
The MojiWeather app has scored over others with users calling their experiences both "accurate and hassle-free."
MojiWeather has revealed that it has received positive user experiences and reviews, and emerged as a top pick in global weather apps, all thanks to its exceptional, all-around performance.
The MojiWeather app has scored over others with users calling their experiences both "accurate and hassle-free." While some apps serve up professional data but feel like an…
Real Estate Listing Agent in Wheatfield, NY, Brings Engineering Background and C …
Wheatfield, NY - Michael "Mick" Trunzo of HUNT Real Estate ERA is transforming the home buying and selling experience by providing a rare combination of technical and mechanical expertise and of course, exceptional real estate knowledge to every client whether they are buying or selling a home or other property. With a 30-year career in engineering prior to entering real estate in 2014, Mick offers clients insights that extend far…
Top Realtor in Wheaton, IL Sees Growing Demand for Deep Community Knowledge and …
Wheaton, IL - In an increasingly competitive real estate landscape, homebuyers and sellers are prioritizing agents with deep local connections and community expertise. Kathryn Pinto, a well-known real estate agent in the area, has witnessed this trend firsthand, as her 20-plus years of Wheaton residency continues to give her clients a distinct advantage in the market.
"Today's clients want more than transaction management - they want someone who truly understands the…
Top Local Movers in Hoboken, NJ Advise Clients on Flexible Scheduling and Altern …
Hoboken, NJ - With moving season approaching, industry professionals are emphasizing the importance of flexible planning and open communication when it comes to scheduling relocations. Unexpected changes to moving dates have become increasingly common, prompting experienced moving companies to develop more adaptable booking policies that accommodate clients' evolving needs while maintaining quality service standards.
Understanding payment structures is essential for anyone planning a relocation. Most long distance movers in Hoboken, NJ…
More Releases for Epidermolysis
Epidermolysis Bullosa Market to Reach USD 6.8 Billion by 2034
Epidermolysis bullosa (EB) is a group of rare, genetic skin disorders characterized by fragile skin that blisters and tears easily. Often referred to as "the butterfly skin disease," EB significantly impacts patients' quality of life and requires long-term supportive care. Historically, treatments were limited to wound management and pain control, but recent advancements in gene therapy, cell-based therapies, and biologics are opening new possibilities for disease-modifying interventions.
Download Full PDF Sample…
Epidermolysis Bullosa Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Epidermolysis Bullosa Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 21+ pipeline drugs in Epidermolysis Bullosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Epidermolysis Bullosa Research. Learn more about…
Epidermolysis Bullosa Pipeline, Clinical Trials Assessment, and FDA Approvals 20 …
DelveInsight's, "Epidermolysis Bullosa Pipeline Insight 2023" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the Epidermolysis Bullosa pipeline landscape. It covers the Epidermolysis Bullosa pipeline drug profiles, including Epidermolysis Bullosa clinical trials and nonclinical stage products. It also covers the Epidermolysis Bullosa therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Epidermolysis Bullosa Market to Reach US$ 3,856.2 Million by 2033
Market Overview:
The 7 major epidermolysis bullosa markets reached a value of US$ 2,496.5 Million in 2022. Looking forward, IMARC Group expects the 7MM to reach US$ 3,856.2 Million by 2033, exhibiting a growth rate (CAGR) of 4% during 2023-2033.
The report offers a comprehensive analysis of the epidermolysis bullosa market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as…
Singapore Dystrophic Epidermolysis Bullosa Treatment Market to Observe Strong De …
Dystrophic Epidermolysis Bullosa Treatment Market: Introduction
According to the report, the global dystrophic epidermolysis bullosa treatment market was valued over US$ 412 Mn in 2019 and is projected to expand at a CAGR of ~5% from 2020 to 2030. Dystrophic epidermolysis bullosa (DEB) is the second most common form of epidermolysis bullosa. The prevalence of DEB varies from 1 per 49,000 inhabitants in Scotland to 1 per 420,168 in the U.S. According to the U.S. National Library of Medicine,…
Epidermolysis Bullosa Market Insights, Share, Size, Companies, and Forecast 2032
DelveInsight's Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Epidermolysis Bullosa Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Epidermolysis Bullosa Market report covers emerging drugs, current treatment practices, market share of individual therapies, and the current forecasted market size…
